How to use AI and machine learning in cell therapy process development

Wednesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

How to use AI and machine learning in cell therapy process development

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

In this webinar you will learn how to best utilize AI and machine learning for cell therapy process development, including design of experiment and a case study on optimizing perfusion in allogeneic T cell manufacturing.

You will find out how to build large datasets for AI development and training and why it’s important that data is pulled from multiple donors and runs.

Using AI and machine learning, we will show the results of an intensive perfusion process that enables cell expansion beyond currently published benchmarks. With this perfusion process, you will discover how machine learning enables scaling in a production bioreactor at 1L scale and with a favorable phenotypic profile.

You will also learn about potential future opportunities for leveraging AI and machine learning in cell therapy process development, as well as potential drawbacks and where this evolving technology should not be applied in CGT development.

How to build large datasets for AI development and training
Results from a case study using machine learning to achieve high T-cell density at half the media cost
Future opportunities to leverage AI and machine learning in cell therapy process development

Alex Sargent

Director of Process Development at Charles River Laboratories

Alex Sargent – better known as “Sarge” – is currently the Director of Process Development at Charles River Laboratories. He obtained his PhD from Case Western Reserve University in Cleveland Ohio, where he studied the challenges and promises of stem cell biology, neuroimmunology, and Cleveland sports teams. After a brief stint in academia at the Cleveland Clinic, he left Cleveland to pursue his industry career in cell therapy. During his many years in this industry, he has had the honor of working at several esteemed enterprises on new technologies and approaches for cell therapy scale up, automation, and gene editing. He is especially passionate about the challenge of curing cancer, working on CAR-T and CAR-NK cell therapy process and analytical development from discovery, through regulatory submission, manufacturing, and pivotal clinical trials. He wakes up each day excited to help advance cell and gene therapy to treat and cure disease, with the steadfast goal of improving human lives.